ARTICLE | Clinical News
Optiquel: Phase I/II started
October 11, 2010 7:00 AM UTC
Enzo began a double-blind, placebo-controlled, U.S. Phase I/II trial to evaluate thrice-weekly 1 and 4 mg oral Optiquel for 24 weeks in about 60 patients. Optiquel has Orphan Drug designation in the E...